Zomedica Corp. (ZOM)

$0.2041

+0.00 (+0.44%)
Rating:
Recommendation:
Buy
Symbol ZOM
Price $0.2041
Beta 0.739
Volume Avg. 6.97M
Market Cap 200.008M
Shares () -
52 Week Range 0.175-0.5
1y Target Est -
DCF Unlevered ZOM DCF ->
DCF Levered ZOM LDCF ->
ROE -6.51% Neutral
ROA -6.20% Neutral
Operating Margin -
Debt / Equity 5.03% Neutral
P/E -10.74 Strong Sell
P/B 0.74 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ZOM news


Mr. Shameze Rampertab
Healthcare
Drug Manufacturers—Specialty & Generic
American Stock Exchange

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.